Merck, Bristol-Myers tout hepatitis C drugs at key AASLD meeting
This article was originally published in Scrip
Executive Summary
Merck & Co and Bristol-Myers Squibb are making their best cases yet to show they’re serious contenders in a race to sell improved treatments for hepatitis C, the virus that destroys the liver and chronically infects millions.